Related Experiment Video

Updated: Jun 23, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia

Xiujuan Xiong1, Min Wang, Lin Wang

  • 1State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, People's Republic of China.

Leukemia Research
|May 9, 2009
PubMed

Insights

The MDM2 SNP309G allele increases acute myeloid leukemia (AML) risk. The homozygous GG genotype for MDM2 SNP309 may be a genetic factor in AML development, but p53 codon 72 interaction was not significant.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Single nucleotide polymorphisms (SNPs) in MDM2 (SNP309 T>G) and p53 (codon 72) are linked to cancer.
  • MDM2 SNP309 affects MDM2 expression, potentially impairing p53 tumor suppressor activity.
  • p53 codon 72 polymorphism alters p53 protein structure.

Purpose of the Study:

  • To investigate the association between MDM2 SNP309 and p53 codon 72 polymorphisms and genetic susceptibility to acute myeloid leukemia (AML).
  • To determine if these polymorphisms influence AML onset or clinical parameters.
  • To explore potential joint effects of these polymorphisms on AML risk.

Main Methods:

  • A case-control study was conducted with 231 AML patients and 128 healthy controls.
  • Genotyping was performed to determine the MDM2 SNP309 and p53 codon 72 polymorphisms.
  • Statistical analysis was used to assess associations and combined effects.

Main Results:

  • The MDM2 SNP309G allele was significantly associated with an increased risk of AML.
  • No association was found between these polymorphisms and age of onset or other clinical parameters.
  • No multiplicative joint effect was observed between MDM2 GG and p53 Pro/Pro genotypes in AML risk.

Conclusions:

  • The MDM2 SNP309 homozygous GG genotype may contribute to the pathogenesis of AML.
  • MDM2 SNP309 and p53 codon 72 polymorphisms do not appear to jointly influence AML risk.
  • Further research is needed to fully elucidate the role of MDM2 SNP309 in AML susceptibility.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair01:36

Mismatch Repair

Overview
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...